Central Pharmaceutical Joint Stock Company No3: H1 2024 saw lower profit and revenue, but improved cash and zero borrowings

About this update from Central Pharmaceutical Jsc No. 3

Revenue and net profit declined year-over-year in H1 2024, with cash position improving and all borrowings repaid. Gross margin remained strong, but financial income and retained earnings decreased. Original document: This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.

View stock analysis, news, and events for Central Pharmaceutical Jsc No. 3